Tiotropium bromide vs Umeclidinium/Vilanterol

NCT02172287 · Phase 3 · completed

This is a large, randomized, double-blind trial with both an active comparator and a placebo arm, using trough FEV1 lung function, the regulator-accepted physiological measure for COPD, as one of its primary endpoints. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

NCT01777334 · Phase 3 · completed

The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.

NCT00772538 · Phase 3 · completed

The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.